Effect of Exposure to Agent Orange on the Risk of Monoclonal Gammopathy and Subsequent Transformation to Multiple Myeloma: A Single-Center Experience From the Veterans Affairs Hospital, Detroit

被引:11
作者
Bumma, Naresh [1 ]
Nagasaka, Misako [1 ]
Hemingway, Griffin [1 ]
Miyashita, Hirotaka [1 ]
Chowdhury, Tahmida [1 ]
Kim, Seongho [1 ]
Vankayala, Hema M. [1 ]
Ahmed, Shabbir [1 ]
Jasti, Pallavi [1 ]
机构
[1] Karmanos Canc Inst, 4100 John R St, Detroit, MI 48201 USA
关键词
MGUS; Monoclonal gammopathy of unknown significance; Myeloma transformation; Pesticide; Progression to myeloma; UNDETERMINED SIGNIFICANCE;
D O I
10.1016/j.clml.2019.11.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Monoclonal gammopathy of undetermined significance is a premalignant condition with the risk of progressing to multiple myeloma (MM). We conducted a retrospective chart review of 211 patients with monoclonal gammopathy seen at John D. Dingell Veterans Affairs Medical Center (Detroit, Michigan). Our study showed an increased risk of MM transformation in patients exposed to Agent Orange. Background: Monoclonal gammopathy of undetermined significance (MGUS) is an indolent, premalignant plasma cell disorder with the potential of transforming into symptomatic multiple myeloma (MM). There are multiple risk factors that contribute to transformation. Agent Orange (AO) has been linked with multiple malignant and nonmalignant conditions. Patients and Methods: We conducted a retrospective chart review of patients with monoclonal gammopathy who were seen at John D. Dingell Veterans Affairs Medical Center (Detroit, Michigan) between 2005 and 2015 with MGUS, smoldering multiple myeloma, and MM. We explored baseline patient characteristics and explored AO exposure. Dates of diagnosis, dates of progression, and expiration dates were recorded to time to progression and overall survival (OS). Results: We identified 211 patients with monoclonal gammopathy; 96% were male and 122 were African American. Eleven patients had reported AO exposure. Cumulative risk of progression in the overall population was 1.4% at 1 year. Risk of transformation in the population exposed to AO was significantly higher with a hazard ratio (HR) of 11.19 (95% confidence interval [CI], 2.10-59.47; P =.005). OS was numerically shorter in AO-exposed patients with a median OS of 7 years compared with 11.1 years in those not exposed. However, AO exposure was not associated with OS in multivariable analysis (HR, 0.50; 95% CI, 0.07-3.83; P =.508). Conclusion: Monoclonal gammopathy is a premalignant condition with the risk of progressing to MM. Exposure to AO has been implicated in multiple conditions including MM. Our study demonstrates an increased risk of progression in exposed patients.
引用
收藏
页码:305 / 311
页数:7
相关论文
共 17 条
  • [1] PESTICIDE EXPOSURES AND MULTIPLE-MYELOMA IN IOWA MEN
    BROWN, LM
    BURMEISTER, LF
    EVERETT, GD
    BLAIR, A
    [J]. CANCER CAUSES & CONTROL, 1993, 4 (02) : 153 - 156
  • [2] Callander NS, 2015, BLOOD, V126
  • [3] How I manage monoclonal gammopathy of undetermined significance
    Go, Ronald S.
    Rajkumar, S. Vincent
    [J]. BLOOD, 2018, 131 (02) : 163 - 173
  • [4] Associations of common variants in genes involved in metabolism and response to exogenous chemicals with risk of multiple myeloma
    Gold, Laura S.
    De Roos, Anneclaire J.
    Brown, Elizabeth E.
    Lan, Qing
    Milliken, Kevin
    Davis, Scott
    Chanock, Stephen J.
    Zhang, Yawei
    Severson, Richard
    Zahm, Sheila H.
    Zheng, Tongzhang
    Rothman, Nat
    Baris, Dalsu
    [J]. CANCER EPIDEMIOLOGY, 2009, 33 (3-4) : 276 - 280
  • [5] Regulation of p53-Targeting MicroRNAs by Polycyclic Aromatic Hydrocarbons: Implications in the Etiology of Multiple Myeloma
    Gordon, Michael W.
    Yan, Fang
    Zhong, Xiaoming
    Mazumder, Pranab Behari
    Xu-Monette, Zijun Y.
    Zou, Dehui
    Young, Ken H.
    Ramos, Kenneth S.
    Li, Yong
    [J]. MOLECULAR CARCINOGENESIS, 2015, 54 (10) : 1060 - 1069
  • [6] Institute of Medicine of the National Academies, 2006, DISP AIR FORC HLTH S
  • [7] Khuder SA, 1997, AM J IND MED, V32, P510, DOI 10.1002/(SICI)1097-0274(199711)32:5<510::AID-AJIM11>3.0.CO
  • [8] 2-5
  • [9] A long-term study of prognosis in monoclonal gammopathy of undetermined significance
    Kyle, RA
    Therneau, TM
    Rajkumar, SV
    Offord, JR
    Larson, DR
    Plevak, MF
    Melton, L
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (08) : 564 - 569
  • [10] Prevalence of monoclonal gammopathy of undetermined significance
    Kyle, RA
    Therneau, TM
    Rajkumar, SV
    Larson, DR
    Plevak, MF
    Offord, JR
    Dispenzieri, A
    Katzmann, JA
    Melton, LJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (13) : 1362 - 1369